Inflammation Testing Prompts Care Changes Leading to Significantly Lower Levels in Patients with Increased Cardiovascular Risk Due to Diabetes or Pre-Diabetes
A study conducted by MDVIP and Cleveland HeartLab found that myeloperoxidase (MPO) levels were reduced over a five-year span in non-diabetic, pre-diabetic and diabetic patients whose MDVIP-affiliated physicians ordered MPO inflammation testing. Researchers attribute this to heightened awareness of cardiovascular risk due to MPO test results and subsequent changes in patient behavior or medication. "We know inflammation is linked to cardiovascular risk. Our research data demonstrates that physicians who monitor the inflammatory status of their patients are successful in helping patients lower their risk based on inflammatory biomarkers,” explains co-author MDVIP Chief Medical Officer Andrea Klemes, D.O., F.A.C.E.